NYU/Bellevue WTC Health Impacts Research Registry
Part of paid clinical trials in New York, New York.
- Sponsor
- NYU Langone Health
- Study ID
- NCT00404898
- Status
- Recruiting
Conditions
- Exposure to World Trade Center Dust
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Accepted
Study Details
The American Red Cross has funded a multidisciplinary, comprehensive evaluation and treatment program for target individuals with suspected World Trade Center (WTC)-related health problems. The populations served consist predominantly of a) local residents who were impacted by the disperion of the WTC dusts and fumes, b) individuals involved in cleaning and debris removal of local commercial spaces, and c) responders to the WTC collapse. These populations are recruited from past and ongoing programs that we have developed as well as from ongoing collaborations with community organizations that include: the Beyond Ground Zero Network, 9/11 Environmental Action committee, and the WTC Residents Coalition. In addition, there is collaboration with the Charles B. Wang Community Health Center and the centers involved in the ongoing WTC Workers and Volunteer Medical Screening and Monitoring Program. We would now like to access the data from this treatment program to create a NYU/Bellevue WTC Health Impacts Research Registry to increase knowledge about the health effects of exposure to World Trade Center dust.
Key Dates
- First listed
- Nov 29, 2006
- Start date
- Dec 31, 2007
- Status verified
- May 2026
- Primary completion
- Sep 30, 2027
- Completion
- Sep 30, 2027
Study Design
- Enrollment
- 40,000 participants (estimated)
Primary Outcome Measure
Respiratory Status [ Time Frame: June 2020 ]
Central Contacts
- Leigh Wilson, DO212-562-1720
- Tatiana Sabin
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| NYU School of Medicine/Bellevue Hospital | New York | New York | 10016 | William Bateman (SUB_INVESTIGATOR) Denise Harrison, MD (SUB_INVESTIGATOR) Andrew Wallach (SUB_INVESTIGATOR) Joan Reibman, MD (PRINCIPAL_INVESTIGATOR) |